What now for NK-cell engagers?
Big pharma interest remains, but the mood is fast turning gloomy.
Neither Arvinas nor Pfizer now wants vepdegestrant
So who else could be interested in the oestrogen degrader?
Lilly moves to overtake Relay
A phase 3 trial of the Scorpion-originated tersolisib will be in first-line breast cancer.
Kura harks back to its roots
After menin, the company tries again with farnesyl transferase.
Chia Tai keeps the TGF-β faith
The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.
Astra and J&J tussle over first-line lung
The companies clash over survival curve similarities – and differences.
Daiichi makes its sting move
The recently unveiled conjugate DS3610a is to start phase 1.
Genmab takes its Profound buy into endometrial
The Rainfol-03 trial, in second-line endometrial cancer, builds on recent early data.
